Pre-clinicals have shown that BA79 can increase the stool volume, fecal water content, food intake and body weight of rats, reduce the vasoactive intestinal peptide VIP in the serum that inhibits gastric motility, and can also significantly improve the operating efficiency of the gastrointestinal tract and regulate intestinal flora, promote nutrient absorption. At the same time, BA79 has strong inhibitory ability against pathogenic bacteria and the ability to utilize functional oligosaccharides.

It can inhibit the growth of Escherichia coli and adhesion to intestinal epithelial cells, improve diarrhea symptoms caused by EIEC, regulate intestinal flora metabolism, improve intestinal absorption efficiency, and at the same time protect immune organs and maintain intestinal barrier function, regulating immunity.

Pre-clinicals show that BL21 can inhibit intestinal flora disorders, improve the metabolism of intestinal flora, and has the potential to promote nutrient absorption and utilization. At the same time, BL21 has strong acid and bile salt resistance and can reach the intestines smoothly. The extracellular polysaccharide it produces also has antioxidant and other functions.

Pre-clinicals show that Lp18 can significantly increase the number of defecation particles and fecal water content in mice. By increasing the levels of excitatory transmitters MTL and SP, and reducing the levels of inhibitory transmitters VIP and SS, it promotes gastric acid secretion in mice and accelerates gastric emptying, accelerate intestinal transit rate and improve gastrointestinal absorption and metabolic efficiency.